G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Cancer
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)...
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic...
ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing...
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions...
ConcertAI’s TeraRecon Launches Three New Care Suites, Life Sciences Platform, and Strategic Partnerships at #ECR24
New Clinical AI care suites for Cardiology, Pulmonology, and Neurology; First-in-Class multi-modal predictive and Gen AI platform for research and...
U.S. Oncology Survey: Employers Expect Cancer Costs to Spike by Up To 30% in Three Years, Hungry for Value-Based Models
U.S. employers frustrated by soaring costs and fragmented solutions share data on specific cancer types and care driving spend, seek...
HIGH Q TECHNOLOGIES SECURES $3.75 MILLION FROM GOVERNMENT OF CANADA TO SUPPORT EXPANSION OF PROTEIN MEASUREMENT PLATFORM FOR DRUG DISCOVERY
Funding through Government of Canada's Regional Quantum Initiative supports product development and commercialization efforts WATERLOO, ON, Feb. 26, 2024 /PRNewswire/...
MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies
LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Today MAX BioPharma, Inc. (www.maxbiopharma.com) and Metaba, LLC (www.metaba.us) announced their collaboration in...
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE...
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery...
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage...
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and...
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Americord Releases Cord Blood Stem Cells for Treatment of Motor Neuron Disease
SOMERSET, NJ / ACCESSWIRE / February 23, 2024 / Americord, a leading private stem cell bank, announced the release of...
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of...
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided...